Background: Epidemiological and microbiologic studies suggest that enteropathogenic microorganisms play a substantial role in the clinical initiation and relapses of inflammatory bowel disease. Aim: To explore the prevalence of intestinal protozoa in patients with ulcerative colitis (UC) and its impact on clinical disease course. Methods: A total of 215 patients with definitive diagnosis of UC were studied. Fresh feces samples taken from all UC patients were examined immediately using trichrome-staining methods. Results: A total of 103 female and 112 male UC patients were analyzed. The mean age at diagnosis was 30.5 ± 10.8 years. The prevalence of overall parasitic infections was 24% and distributed as follows: Blastocystis hominis in 22 patients (10%), Endolimax nana in 19 cases (9%), and Entamoebahistolytica in 11 cases (5%). A significantly increased frequency of protozoa infection was found in those patients with persistent activity and intermittent activity as compared to active than inactive group (p = 1 × 10–7, OR 13.05, 95% CI 4.28–42.56, and p = 0.003, OR 1.42–14.47, respectively). Interestingly, this association remained significant when we compared the persistent activity group versus intermittent activity group (p = 0.003, OR 2.97, 95% CI 1.35–6.59). Subgroup analysis showed no association between protozoa infection (E. histolytica, B. hominis, and E. nana) and other clinical variables such as gender, extent of disease, extraintestinal complications, medical treatment and grade of disease activity. Conclusion: The prevalence of intestinal protozoa infections in Mexican UC patients was 24% and these microorganisms could be a contributing cause of persistent activity despite medical treatment in our population.

Journal Section:
Original Paper
Keywords:
Protozoa infections, intestinal, Ulcerative colitis, Enteropathogenic microorganisms
1.
WHO: World Health Report 2000 – Conquering Suffering Enriching Humanity. Geneva, World Health Organization 2000.
2.
Yamamoto-Furusho JK: Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20 year period (1987–2006). J Clin Gastroenterol 2009;43:221–224.
[PubMed]
https://doi.org/10.1097%2FMCG.0b013e31817a76b4
3.
Andersen PL: Amebiasis. Ugeskr Laeger 2000;162:1537–1541.
[PubMed]
4.
Hansen LH, Lund C: Amebiasis – a differential diagnosis from inflammatory bowel disease. Ugeskr Laeger 1998;160:5514–5515.
[PubMed]
5.
Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al; IBSEN Study Group: Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543–550.
[PubMed]
https://doi.org/10.1097%2F01.MIB.0000225339.91484.fc
6.
Bayramicli OU, Dalay R, Konuksal F, Kilic G, Akbayir N, Ovunc O: Ulseratif kolitle amebiasisin birlikteligi. Turk J Gastroenterol 1997;8:94–96.
7.
Süleymanlar I, Atilgan S, Ertugrul C, Isitan F: Ulseratif kolit ve intestinal amebiasis birlikteligi ve tedavide karsilasilan sorunlar. Gastroenteroloji 1996;7:22.
8.
Prokopowicz D, Zagorski K, Kramarz P: Amoebiasis – a problem in patients with ulcerative colitis. Wiad Lek 1994;47:248–251.
[PubMed]
9.
Chan KL, Sung JY, Hsu R, Liew CT: The association of the amoebic colitis and chronic ulcerative colitis. Singapore Med J 1995;36:303–305.
[PubMed]
10.
Ustün S, Turgay N: Blastocystis hominis and bowel diseases. Turkiye Parazitol Derg 2006;30:72–76.
[PubMed]
11.
Dogruman-Al F, Kustimur S, Yoshikawa H, Tuncer C, Simsek Z, Tanyuksel M, Araz E, Boorom K: Blastocystis subtypes in irritable bowel syndrome and inflammatory bowel disease in Ankara, Turkey. Mem Inst Oswaldo Cruz 2009;104:724–727.
[PubMed]
12.
Wang LJ, Cao Y, Shi HN: Helminth infections and intestinal inflammation. World J Gastroenterol 2008;14:5125–5132.
[PubMed]
https://doi.org/10.3748%2Fwjg.14.5125
13.
Salas SD: Intestinal parasites in Central American immigrants in the United States. Arch Intern Med 1990;150:1514–1516.
[PubMed]
https://doi.org/10.1001%2Farchinte.150.7.1514
14.
Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS: Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008;135:781–786.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2008.05.081
15.
McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G: Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100–113.
[PubMed]
https://doi.org/10.1002%2Fibd.20539
16.
Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M: Epithelial tight junctions in intestinal inflammation. Ann NY Acad Sci 2009;1165:294–300.
[PubMed]
https://doi.org/10.1111%2Fj.1749-6632.2009.04062.x
17.
Lidar M, Langevitz P, Shoenfeld Y: The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. Isr Med Assoc J 2009;11:558–563.
[PubMed]
18.
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004;127:412–421.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2004.04.061
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.